evipedia.ai
← Back

Niacin for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: Nicotinic Acid, Vitamin B3, Niaspan, Extended-Release Niacin, Immediate-Release Niacin

Motivation

Niacin (vitamin B3) is one of the oldest vitamins in clinical use and one of the strangest. In small amounts it is a nutrient the body cannot do without: every cell needs it to build the molecule that turns food into usable energy and that powers the repair of damaged DNA. In amounts a hundred times larger it stops behaving like a vitamin and starts behaving like a drug, reshaping blood fats more broadly than almost anything else available without a prescription.

That dual identity has produced a long and unusually contested record. Niacin was the first cholesterol-lowering agent shown to reduce heart attacks, decades before today’s standard treatments existed. It then spent thirty years as a mainstream prescription therapy, before two very large trials in people already on modern cholesterol-lowering treatment found no added benefit and an unexpected list of harms; the branded products were withdrawn. Interest has since returned from an entirely different direction — research on how cells age.

This review examines what niacin does at nutritional and at pharmacological doses, how firm the evidence is behind each claimed effect, what the harms are and how they scale with dose, and where genuine uncertainty remains.

Benefits - Risks - Protocol - Conclusion

High-level overviews of niacin from clinicians, researchers and longevity-focused publications that treat the compound in substantial depth.

Note on prioritized experts: Peter Attia, Lifespan.io, Life Extension and FoundMyFitness each yielded a qualifying, openly readable item, and a narrative review from the clinical literature completes the list. FoundMyFitness also treats high-dose niacin and cardiovascular risk at greater length in a members-only Q&A episode, which is not cited here because it cannot be read without a paid subscription. Huberman Lab’s site search returns only timestamped fragments inside broader episodes — the nicotinamide form for skin, eye and satiety questions — rather than any item that treats niacin itself in depth. Chris Kresser’s site search returns several articles that mention niacin — a skin-nutrition piece in which it is one of four nutrients, and a podcast episode on lipoprotein(a) that covers it in a single passage — but none treats the compound in depth.

Grokipedia

  • Nicotinic acid

    Covers the compound’s chemistry, its role as a precursor to the cell’s central energy cofactor, and its pharmacological use, giving structural and metabolic detail this review summarizes only briefly.

Examine

  • Niacin (Vitamin B3)

    Grades outcomes against 103,792 participants across 11 trials and 5 meta-analyses, and separates nicotinic acid from the flush-free forms that share the vitamin B3 label but not the lipid effects.

ConsumerLab

Systematic Reviews

The highest-tier evidence on niacin, selected to cover both its claimed benefits and its principal harms.

Mechanism of Action

Niacin acts through two largely separate routes, and the dose decides which one dominates.

At nutritional doses it enters the Preiss–Handler pathway (a three-step conversion route), where the enzyme NAPRT (nicotinate phosphoribosyltransferase, which attaches a sugar-phosphate group to niacin) begins its conversion into NAD+ (nicotinamide adenine dinucleotide, the cofactor cells use for energy release, DNA repair, and sirtuin activity — a family of enzymes tied to cellular repair).

At gram doses a second mechanism takes over. Niacin binds GPR109A (also written HCAR2, a receptor on fat cells and skin immune cells), suppressing cyclic AMP (an internal chemical messenger) and therefore hormone-sensitive lipase (the enzyme that releases stored fat). The liver then receives fewer fatty acids and assembles fewer triglyceride-rich particles. Niacin additionally inhibits DGAT2 (diacylglycerol acyltransferase 2, the last enzyme of triglyceride assembly), accelerating breakdown of newly made apolipoprotein B, and slows liver removal of HDL particles. Lipoprotein(a) falls through reduced production of its apolipoprotein(a) component.

Two mechanistic readings compete. The classical account credits the HDL increase; the alternative credits apolipoprotein B and lipoprotein(a) lowering and treats the HDL change as a bystander.

Immediate-release niacin has a plasma half-life of roughly 20–45 minutes, distributes to liver, fat and skin, and is cleared by two saturable liver routes: glycine conjugation, which drives the flush, and amidation via NNMT (nicotinamide N-methyltransferase, which spends methyl groups) to the terminal waste metabolites 2PY and 4PY.

Historical Context & Evolution

Niacin entered medicine as a cure, not a supplement. Joseph Goldberger’s field work in the American South established that pellagra (a fatal deficiency disease) was dietary rather than infectious, and Conrad Elvehjem isolated the active factor in 1937. Fortification of flour followed, and pellagra effectively disappeared from industrialized countries.

Its second life began in 1955, when Rudolf Altschul reported that gram doses lowered serum cholesterol — the first drug of any kind shown to do so. The Coronary Drug Project, running from 1966, randomized 8,341 men with prior heart attacks; niacin modestly reduced non-fatal reinfarction, and at fifteen-year follow-up, nine years after the drug was stopped, mortality was 11% lower than placebo. Extended-release Niaspan was approved in 1997, and combination trials showed plaque regression on imaging.

The reversal came in the statin era. AIM-HIGH, funded by the National Heart, Lung, and Blood Institute together with Abbott Laboratories — the manufacturer of the extended-release niacin under test — stopped early for futility in 2011. HPS2-THRIVE, funded by Merck, whose flush-blocking add-on laropiprant was the product being commercialized, reported no benefit and new harms in 2014. Branded combination products were withdrawn.

What changed was the comparator, not the compound: both modern trials tested niacin added to intensive statin therapy in people already at very low LDL cholesterol (low-density lipoprotein, the main artery-clogging particle), a question the older trials never asked. Whether niacin retains value where statins are absent or not tolerated, or where lipoprotein(a) is the target, remains open.

Expected Benefits

High 🟩 🟩 🟩

Lowering of Apolipoprotein B and LDL Cholesterol

Niacin reduces the number of artery-invading particles, not only the cholesterol they carry. A meta-analysis of 12 randomized controlled trials (RCTs — trials that assign participants to treatment or placebo by chance) found apolipoprotein B (ApoB, the single protein carried by every artery-clogging particle, so it counts them) fell substantially. In the 25,673-participant HPS2-THRIVE trial, 2 g daily lowered LDL cholesterol even on top of intensive statin therapy.

Magnitude: ApoB −24.4 mg/dL as a weighted mean difference (the average difference across trials, weighted by trial size) across 12 RCTs; LDL cholesterol −10 mg/dL at 2 g daily added to intensive statin therapy, and roughly 10–20% when used alone.

Reduction of Lipoprotein(a)

Lipoprotein(a) is a largely genetically fixed, unusually artery-damaging particle that diet, exercise and statins barely move. Extended-release niacin is one of very few widely available agents that lowers it. A meta-analysis of 14 placebo-controlled RCTs in 9,013 people found a consistent reduction that was unrelated to dose, treatment duration or the HDL change — evidence for a separate mechanism. Whether lowering lipoprotein(a) by this margin reduces events has never been tested directly.

Magnitude: −22.9% (95% CI −27.3 to −18.5; CI = confidence interval, the range within which the true value most likely lies), comparable below and above 2 g daily.

Elevation of HDL Cholesterol and Apolipoprotein A-I

Niacin remains the most powerful oral agent for raising HDL cholesterol. Pooled RCT data show apolipoprotein A-I, the main HDL protein, rising chiefly above 1,500 mg daily and with extended-release forms; AIM-HIGH recorded a rise from 35 to 42 mg/dL. The effect itself is not disputed. Its value is: in both large modern trials the HDL increase produced no reduction in events.

Magnitude: Apolipoprotein A-I +8.2 mg/dL; HDL cholesterol +20% (35 → 42 mg/dL) at 1,500–2,000 mg daily over two years.

Reduction of Triglycerides

Niacin lowers triglycerides by suppressing fatty-acid release from fat tissue and blocking the final step of triglyceride assembly in the liver. A meta-analysis of randomized trials in people with type 2 diabetes found a consistent fall, and AIM-HIGH recorded the same effect on top of intensive statin therapy in a broader population. The change appears within weeks and is among the largest available without a prescription. As with the other lipid changes, it has not been shown to reduce events when added to a statin.

Magnitude: −0.39 mmol/L (95% CI −0.43 to −0.34), roughly −35 mg/dL, pooled across randomized trials in type 2 diabetes; 164 → 122 mg/dL (−26%) at 1,500–2,000 mg daily in AIM-HIGH.

Medium 🟩 🟩

Reversal of Niacin Deficiency and Pellagra

Frank deficiency causes pellagra — dermatitis on sun-exposed skin, diarrhoea and confusion — and is fatal untreated. Replacement reverses it, one of the most reliable responses in clinical nutrition, though the evidence base is consistent clinical series and historical work on the tryptophan–niacin relationship rather than modern trials. For this audience the relevance is narrow: deficiency now appears mainly with alcohol use disorder, bariatric surgery, carcinoid tumours (hormone-secreting gut growths), isoniazid therapy, or Hartnup disease (an inherited defect in absorbing tryptophan).

Magnitude: Skin and gastrointestinal signs typically resolve within days of replacement and neurological signs within weeks; the literature reports no controlled outcome figure, because withholding treatment from deficient patients is not ethical.

Slowed Progression and Regression of Atherosclerosis

Imaging trials consistently show niacin altering atherosclerosis (fatty plaque build-up inside artery walls), not only lipids. In the HATS trial, 160 patients with coronary disease and low HDL were randomized across four regimens, and average narrowing regressed on simvastatin plus niacin while placebo progressed. A meta-analysis of 11 RCTs found substantially more patients with coronary regression and slower thickening of the carotid artery wall. The limitation is decisive: nearly all these trials combined niacin with another lipid drug, so the niacin-specific contribution is not isolated.

Magnitude: Coronary narrowing regressed 0.4% versus 3.9% progression on placebo over three years; 92% more patients showed regression, and carotid intima–media thickness (the ultrasound-measured thickness of the inner artery wall) increased 17 µm/year less.

Improved Endothelial Function

Flow-mediated dilation (how much an artery widens when blood flow rises, a marker of blood-vessel lining health) predicts future cardiovascular events. A meta-analysis of 7 RCTs in 441 people found niacin improved it, with larger effects at 2 g daily or above and in people without established disease. Meta-regression (a statistical test of what explains differences between trials) found no association with the HDL, LDL or triglyceride changes, suggesting a direct vascular action. The contributing trials were small and short.

Magnitude: +1.98 percentage points of flow-mediated dilation (95% CI 0.91–3.05), with no measurable effect on nitroglycerin-mediated dilation.

Reduction of Systemic Inflammatory Markers

A meta-analysis of 15 RCTs found niacin lowered C-reactive protein (CRP, a general blood marker of inflammation), with the effect concentrated in trials under 24 weeks, doses at or below 1,000 mg daily, and starting CRP above 3 mg/L. Tumour necrosis factor alpha (an inflammatory signalling protein) also fell; interleukin-6 (another inflammatory signal) did not change significantly. Adiponectin and leptin (hormones released by fat tissue) rose. The inconsistency across markers keeps this below the top tier.

Magnitude: CRP standardized mean difference −0.88 (95% CI −1.46 to −0.30); adiponectin +3.52 and leptin +1.90, all expressed in standard deviations rather than absolute units.

Low 🟩

Reduction of Cardiovascular Events ⚠️ Conflicted

Older trials in people not taking statins found benefit, and Coronary Drug Project mortality was lower fifteen years on. Statin-era trials and the Cochrane review found none. Net: any event benefit appears confined to statin-free settings and to trial populations from a different treatment era.

Magnitude: Relative risk 0.74 (95% CI 0.58–0.96; relative risk = the ratio of event rates between two groups) for acute coronary syndrome with niacin alone in statin-free trials, versus risk ratio 1.05 (0.97–1.12) for all-cause mortality across the 12 trials pooled by the Cochrane review.

Lower Mortality at Higher Dietary Intake

Among 26,746 US adults followed a median 9.2 years, the highest quartile of dietary niacin intake had lower all-cause and cardiovascular mortality than the lowest. This measures food intake, not supplementation, and is open to confounding by overall diet quality.

Magnitude: Hazard ratio 0.74 (95% CI 0.63–0.86; hazard ratio = the relative rate at which an outcome occurs over time) for all-cause and 0.73 (0.57–0.95) for cardiovascular mortality, highest versus lowest intake quartile.

Lower Odds of Glaucoma

A meta-analysis of five case-control studies found people with glaucoma (progressive optic-nerve damage, usually with raised eye pressure) reported lower daily niacin intake. Case-control design and recall-based dietary data leave causation unresolved; no randomized trial of niacin in glaucoma exists.

Magnitude: Odds ratio 0.66 (95% CI 0.55–0.79; odds ratio = the relative odds of an outcome between two groups) for glaucoma with high versus low niacin intake.

Restoration of NAD+ with Improved Muscle Performance

In adults with mitochondrial myopathy (an inherited muscle disease caused by faulty cellular power plants), escalating niacin to 750–1,000 mg daily for ten months raised blood NAD+ up to eightfold and increased muscle strength. The trial was small, open-label and uncontrolled, and some patients tended toward anaemia.

Magnitude: Blood NAD+ rose up to 8-fold from baseline over ten months, with muscle NAD+ in patients reaching control levels; the trial reports directional strength gains rather than a pooled effect size.

Reduced Liver Fat

In the same open-label NAD+ trial, liver fat fell by roughly half over ten months. A randomized crossover trial of 750 mg daily in fatty liver disease is now recruiting. The existing finding is uncontrolled, small, and drawn from an unusual population.

Magnitude: Liver fat content fell about 50% over ten months at 750–1,000 mg daily in an uncontrolled trial.

Improved Motor Function in Parkinson Disease

A single-centre randomized trial in US veterans gave 100 mg daily for six months. Motor scores moved slightly in niacin’s favour but did not separate from placebo, and the later gains came from an uncontrolled open-label phase. The rationale is that the receptor niacin binds is upregulated in Parkinson disease.

Magnitude: Unified Parkinson’s Disease Rating Scale part III changed −1.06 on niacin versus −0.05 on placebo over six months at 100 mg daily, a gap the trial was not powered to detect.

Speculative 🟨

Healthspan Extension via NAD+ Restoration

NAD+ declines with age, and restoring it extends lifespan in yeast and worms and improves function in aged mice. No human study has measured an ageing outcome with niacin; the basis is animal only.

Antitumour Immune Activation

Preclinical work reports niacin reprogramming tumour-associated immune cells in brain-cancer models. The basis is animal and cell-culture work only; no human trial has tested niacin as a cancer therapy.

Benefit-Modifying Factors

  • Baseline lipoprotein(a) and triglycerides: Percentage reductions are proportionally similar across the range, so absolute benefit scales with the starting value. Someone with lipoprotein(a) at 150 nmol/L gains far more absolute reduction than someone at 20 nmol/L.

  • Baseline inflammation: The C-reactive protein effect appeared only in trials where participants started above 3 mg/L. Those already below that threshold showed no measurable anti-inflammatory response.

  • Baseline NAD+ status: The clearest functional gains came from people with documented systemic NAD+ deficiency. Where NAD+ is already sufficient, the added supply is cleared as methylated waste rather than used.

  • Pre-existing conditions: Benefit is largest in established cardiovascular disease with residual apolipoprotein B or lipoprotein(a) elevation, and in mitochondrial disease. Diabetes, fatty liver and gout do not reduce the lipid effect but shift the balance against it.

  • Genetic variation in metabolism and response: Activity of NNMT and NAPRT, the enzymes that clear and activate niacin, sets the balance between NAD+ production and terminal metabolite accumulation. Variants of MTHFR (the gene that regenerates methyl groups) may further shift this balance.

  • Concurrent statin therapy and age: Adding niacin to intensive statin therapy has produced no incremental event benefit in anyone. Age matters indirectly: NAD+ falls and lipoprotein(a) risk accumulates with age, but so does diabetes susceptibility.

  • Sex: Women reach higher plasma niacin concentrations at equal doses and report flushing more often, and showed larger LDL cholesterol and triglyceride reductions in lipid trials; no trial has demonstrated a sex difference in clinical outcomes.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Cutaneous Flushing

Within 15–30 minutes of an immediate-release dose most people develop intense facial and upper-body redness, warmth and prickling. It is mediated by GPR109A on skin immune cells releasing prostaglandin D2 (a local messenger that widens blood vessels), and is physiologically harmless but frequently intolerable. Across 17 trials, stopping treatment because of side effects was more than twice as likely on niacin, and about a third of HPS2-THRIVE candidates failed a one-month tolerance run-in. Tolerance usually develops over several weeks of uninterrupted dosing.

Magnitude: Risk ratio 2.17 (95% CI 1.70–2.77) for discontinuation due to side effects across 17 trials; roughly one-third of screened candidates were excluded during a one-month run-in.

New-Onset Type 2 Diabetes and Worsened Glycemic Control

Niacin raises fasting glucose and insulin resistance, probably through rebound release of fatty acids once the fat-suppressing effect wears off. Across 11 RCTs in 26,340 non-diabetic participants, niacin increased new diabetes diagnoses by a third. In people who already have diabetes, serious loss of control was substantially more likely. For a metabolically healthy person taking niacin for prevention, this is the single most consequential harm.

Magnitude: Risk ratio 1.34 (95% CI 1.21–1.49) for new-onset diabetes, equal to one extra case per 43 people treated for five years; hazard ratio 1.56 (1.35–1.80) for serious disturbance of diabetes control in existing diabetes.

Hepatotoxicity

Hepatotoxicity (liver injury) arises because the amidation clearance route saturates at high doses, generating metabolites that stress liver cells. In HPS2-THRIVE, sustained elevation of alanine aminotransferase (a liver enzyme released when liver cells are damaged) occurred more often on niacin. The severe risk is formulation-specific rather than dose-specific: unregulated sustained-release products have caused fulminant liver failure at doses immediate-release niacin tolerates.

Magnitude: Alanine aminotransferase above three times the upper limit of normal on consecutive tests in 0.10% per year at 2 g daily versus 0.06% per year on placebo; fulminant failure with sustained-release products appears only as case reports.

Myopathy When Combined with Statins

Adding extended-release niacin with laropiprant to simvastatin 40 mg raised definite myopathy (muscle damage with pain and enzyme release) more than fourfold, with a small number of rhabdomyolysis cases (severe muscle breakdown that can injure the kidneys). Risk concentrated in Chinese participants, whose statin myopathy rates were already higher, a pharmacogenetic signal relevant to anyone of East Asian ancestry combining the two.

Magnitude: Definite myopathy 0.16%/year versus 0.04%/year (risk ratio 4.4, 95% CI 2.6–7.5); any myopathy in Chinese participants 0.66%/year versus 0.13%/year, against 0.07% versus 0.04% in European participants.

Medium 🟥 🟥

Excess Serious Infection and Bleeding ⚠️ Conflicted

HPS2-THRIVE found unexplained excesses of serious infection and serious bleeding, neither predicted by any prior mechanism. A subsequent US Food and Drug Administration Sentinel cohort of 210,389 matched pairs found no excess of major gastrointestinal bleeding or brain haemorrhage for extended-release niacin against fenofibrate. Net: the bleeding signal is unconfirmed outside that single trial and may belong to laropiprant, the flush-blocking drug given alongside niacin there, while the infection signal remains unexplained.

Magnitude: Absolute excess of 4 serious infections and 2 serious bleeds per 1,000 person-years in HPS2-THRIVE; hazard ratio 0.98 (95% CI 0.82–1.18) for major gastrointestinal bleeding in the post-marketing comparison.

Gastrointestinal Intolerance

Nausea, indigestion, vomiting and diarrhoea are common, and niacin can reactivate peptic ulcer disease. HPS2-THRIVE recorded an absolute excess in serious gastrointestinal adverse events over a median 3.9 years, and gastrointestinal complaints were among the leading reasons participants stopped treatment. Taking each dose with food reduces but does not remove the problem.

Magnitude: Absolute excess of 1.0 percentage point in serious gastrointestinal adverse events over a median 3.9 years at 2 g daily.

Low 🟥

Hyperuricemia and Gout Flares

Hyperuricemia (raised blood uric acid) develops because niacin competes with uric acid for excretion by the kidney tubules, precipitating gout (sudden inflammatory joint pain from urate crystals) in susceptible people. Niacin appears on standard lists of urate-raising drugs alongside thiazide diuretics (a widely used blood-pressure drug class) and low-dose aspirin.

Magnitude: Not quantified in available studies. No controlled trial has reported gout incidence as a prespecified endpoint for niacin, so the association rests on urate measurements and case reports.

Niacin Maculopathy

High doses can cause cystoid macular oedema (fluid pockets in the central retina that blur vision), characteristically without the dye leakage seen in other causes. It is dose-dependent and reverses on dose reduction or withdrawal.

Magnitude: Estimated at about 0.67% of patients treated for high cholesterol, with most reported cases above 3 g daily, onset between one and 36 months, and vision recovering within four to eight weeks of stopping.

Association of Terminal Metabolites with Cardiovascular Events ⚠️ Conflicted

A 2024 analysis linked the breakdown products 4PY and 2PY to major cardiovascular events across three cohorts, with 4PY inducing vascular adhesion molecules in mice. Metabolite levels were measured, not assigned, and reflect food fortification rather than supplements. Net: a plausible but unproven explanation for niacin’s failure to reduce events.

Magnitude: Adjusted hazard ratio 1.89 (95% CI 1.26–2.84) for 4PY and 1.64 (1.10–2.42) for 2PY over three years, highest versus lowest levels.

Orthostatic Hypotension and Dizziness

Orthostatic hypotension (a blood-pressure drop on standing) follows the same blood-vessel widening that produces flushing, causing light-headedness or fainting, particularly with the first doses, on an empty stomach, after alcohol or a hot shower, or alongside blood-pressure medication. It eases as flush tolerance develops over the first weeks.

Magnitude: Not quantified in available studies. Trials report dizziness only inside pooled side-effect tallies, so no separate incidence figure exists.

Cutaneous Hyperpigmentation and Dry Skin

Chronic gram doses can produce acanthosis nigricans (velvety brown thickening of skin folds at the neck and armpits), probably through niacin-driven insulin resistance. A systematic review of drug-induced cases found nicotinic acid the most frequently implicated drug alongside insulin. Dry skin is common too; both regress after withdrawal.

Magnitude: Not quantified in available studies. No controlled trial has reported skin pigmentation as an endpoint, so the evidence rests on case reports and a systematic review of those reports.

Speculative 🟨

Methyl-Group Depletion

Clearing surplus niacin consumes S-adenosylmethionine, the body’s main methyl donor. Chronic gram doses could in principle strain methylation capacity and raise homocysteine. No human trial has tested this over longevity-relevant durations.

Risk-Modifying Factors

  • Insulin resistance and prediabetes: The strongest single risk modifier. Those already glucose-intolerant carry both the highest absolute chance of crossing into diabetes and the highest chance of serious loss of glycemic control.

  • Baseline liver enzymes and alcohol intake: Pre-existing transaminase elevation, fatty liver, or regular alcohol use compound niacin’s hepatic load, because both are cleared through overlapping oxidative capacity in the liver.

  • East Asian ancestry with concurrent statin use: Myopathy rates in Chinese participants were roughly ten times those in European participants at identical doses, plausibly reflecting SLCO1B1 (a liver statin-transporter gene) variants that raise statin exposure.

  • Baseline urate and gout history: Anyone with prior gout or serum urate near the saturation threshold faces a materially higher chance of a flare, since niacin acts on the same renal excretion route.

  • Age and polypharmacy: Older users more often combine niacin with statins, antihypertensives and antiplatelet drugs, compounding myopathy, hypotension and bleeding concerns, and they clear the drug more slowly.

  • Sex: Women reach higher plasma concentrations at equal doses and report flushing and hypotensive symptoms more frequently; no sex difference in serious adverse events was demonstrated in the large trials.

Key Interactions & Contraindications

  • Statins (simvastatin, atorvastatin, rosuvastatin, lovastatin): Caution, with a fourfold increase in definite myopathy and occasional rhabdomyolysis. Practice is to cap simvastatin at 20 mg alongside niacin, favour rosuvastatin or pravastatin, and measure creatine kinase (an enzyme released from damaged muscle) when muscle pain appears.

  • Antidiabetic medication — blood-sugar-lowering drugs (metformin, sulfonylureas, insulin): Monitor closely. Niacin raises glucose and can unmask or worsen diabetes, requiring upward dose adjustment. Fasting glucose is typically re-checked four to eight weeks after each niacin dose increase.

  • Antihypertensives, nitrates and alpha-blockers — blood-pressure-lowering drugs (amlodipine, isosorbide mononitrate, tamsulosin): Caution for additive blood-vessel widening causing severe low blood pressure and fainting. Mitigation is separation of dosing by several hours, with niacin taken with food at night.

  • Anticoagulants and antiplatelets — blood-thinning drugs (warfarin, apixaban, clopidogrel, aspirin): Monitor. A bleeding excess appeared in one large trial and was not reproduced in post-marketing data, so monitoring for bruising replaces pre-emptive dose adjustment.

  • Bile acid sequestrants — drugs that bind cholesterol in the gut (colesevelam, cholestyramine, colestipol): Caution for reduced niacin absorption. Administration is separated by at least four hours, with niacin one hour before or four hours after the sequestrant.

  • Alcohol and hot beverages: Caution. Both amplify flushing and hypotension by widening blood vessels through independent routes. Abstinence from alcohol and hot drinks for one to two hours around each dose limits this.

  • Blood-pressure-lowering supplements (beetroot nitrate, citrulline, arginine, garlic extract, magnesium): Caution for additive hypotension. These share niacin’s vasodilatory direction, so separated timing and single-agent introduction are usual.

  • NAD+ precursor supplements (nicotinamide riboside, nicotinamide mononucleotide, nicotinamide): Caution for additive methyl-group consumption and redundant NAD+ loading. There is no evidence of added benefit from stacking, and terminal metabolite burden rises.

  • Isoniazid, azathioprine, mercaptopurine and carbidopa: Monitor. These deplete or compete within the niacin–tryptophan pathway, changing requirements in either direction; niacin status should be assessed rather than assumed.

  • Thyroid function and urine glucose testing: Monitor. Niacin can lower total thyroxine and thyroxine-binding globulin (the carrier protein for thyroid hormone), and can give false-positive urine glucose results, so current use is recorded before any such test.

Populations who should avoid Niacin:

  • Active liver disease, unexplained transaminase elevation, or alanine aminotransferase above three times the upper limit of normal
  • Active peptic ulcer disease or arterial bleeding
  • Uncontrolled type 2 diabetes with HbA1c (glycated haemoglobin, a three-month average of blood sugar) above 8.0%, or type 1 diabetes without specialist supervision
  • Gout with a flare in the preceding twelve months, or serum urate above 8 mg/dL
  • Pregnancy and breastfeeding at doses above the recommended dietary allowance
  • Unstable angina or acute myocardial infarction within the preceding 90 days
  • Any use of sustained-release niacin formulations not manufactured under pharmaceutical quality control

Risk Mitigation Strategies

  • Low starting dose with slow escalation: Beginning at 100 mg once daily and doubling every one to two weeks lets flushing tolerance develop, which is the main reason people abandon niacin before reaching an effective dose.

  • Immediate-release or prescription extended-release rather than unregulated sustained-release: Sustained-release products drive the fulminant liver failure cases, so this single choice removes the most severe documented hepatic risk.

  • Dosing with food at the end of the day: Food slows absorption and blunts the flush peak; evening dosing means any flushing or light-headedness occurs while at rest rather than while driving or exercising.

  • Aspirin 325 mg 30 minutes before the dose: Aspirin blocks the prostaglandin D2 release that causes flushing, cutting its intensity substantially during the first weeks when discontinuation risk is highest.

  • Glucose screening before and during use: Fasting glucose and HbA1c at baseline, then at 6–8 weeks and every 3–6 months, catches the drift toward diabetes that is niacin’s most likely serious harm.

  • Liver enzymes at baseline, 6–12 weeks and twice yearly: Sustained alanine aminotransferase above three times the upper limit of normal is the accepted stop signal, and detecting it early prevents progression to clinical hepatitis.

  • Abstinence from alcohol and hot showers around dosing: Both widen blood vessels independently and stack with niacin’s own effect, converting a tolerable flush into hypotension and fainting.

  • A 2 g daily ceiling outside specialist supervision: Adverse effects rise steeply above this, and no lipid benefit above 2 g has been demonstrated for lipoprotein(a) or apolipoprotein B.

Therapeutic Protocol

  • Conventional lipid protocol: Extended-release niacin 500 mg at bedtime, increased by 500 mg every four weeks to 1,500–2,000 mg daily — the Niaspan labelling schedule, carried into wide lipid-clinic use by the AIM-HIGH investigators under William Boden.

  • Integrative and orthomolecular protocol: Immediate-release niacin 500 mg two to three times daily with meals, escalated from 100 mg. Descends from Abram Hoffer’s orthomolecular work, and is favoured where flush-mediated vasodilation is considered desirable.

  • NAD+ repletion protocol: Niacin escalated over weeks to 750–1,000 mg daily, the schedule used by Pirinen and colleagues in Helsinki, aimed at restoring cellular NAD+ rather than at lipid change. No consensus protocol exists.

  • Best time of day: Evening or bedtime is standard, so that flushing and any light-headedness occur at rest. Cholesterol synthesis also peaks overnight, aligning with the drug’s hepatic effects.

  • Half-life: Immediate-release niacin clears in roughly 20–45 minutes; extended-release formulations stretch absorption over 8–12 hours, which is why the two forms differ so sharply in flushing and hepatic burden.

  • Single versus split dosing: Extended-release is taken once nightly. Immediate-release above 500 mg is split across two or three meals, because single large doses saturate the conjugative clearance route and intensify flushing.

  • Genetic considerations: MTHFR and NNMT variants affecting methyl-group supply may argue for lower doses or adequate folate and B12 intake. SLCO1B1 variants raising statin exposure argue against combining niacin with high-dose simvastatin.

  • Sex-based considerations: Women reach higher plasma concentrations per milligram and report more flushing, so slower escalation is common. No trial has shown that women require a different target dose for lipid effects.

  • Age-related considerations: Beyond 65, slower hepatic clearance, more concurrent medication and higher baseline diabetes risk all argue for the lower end of the range and more frequent laboratory review.

  • Baseline biomarker considerations: Lipoprotein(a) above 125 nmol/L, apolipoprotein B above 90 mg/dL, or documented NAD+ deficiency define the situations where a measurable target exists. Without one, there is nothing to titrate against.

  • Pre-existing condition considerations: Prediabetes, fatty liver, gout and peptic ulcer disease each shift the risk-benefit balance unfavourably and are the conditions most likely to make niacin the wrong choice.

Discontinuation & Cycling

  • Intended duration: Lipid use is open-ended, since lipoprotein(a) and apolipoprotein B return to baseline within weeks of stopping. NAD+ repletion use is typically framed as a defined course against a measured deficiency.

  • Withdrawal effects: None described. Niacin produces no dependence or rebound syndrome; lipid values simply drift back toward their pre-treatment levels over roughly four to six weeks.

  • Tapering: Not required for safety. A taper is nonetheless often used because abrupt cessation and restart forfeits flush tolerance, which then has to be rebuilt from a low dose.

  • Cycling: No efficacy argument supports cycling, as the lipid effect does not attenuate with continued use. Some practitioners schedule breaks to allow liver enzymes and glucose to be assessed off-drug.

  • Restarting after an interruption: After a break longer than about three days, flush tolerance is largely lost. Restarting at a reduced dose and re-escalating avoids an unnecessarily severe reaction.

Sourcing and Quality

  • Form is the decisive variable: Only nicotinic acid produces the lipid effects. Products labelled “no-flush niacin” contain inositol hexanicotinate or nicotinamide, which correct deficiency but do not reproduce the lipid or lipoprotein(a) changes.

  • Unregulated sustained-release products are the one form to rule out: The documented fulminant liver failure cases involve sustained-release preparations. Immediate-release, or prescription extended-release manufactured to pharmaceutical standards, are the two defensible choices.

  • Third-party testing: NSF Certified for Sport, USP Verified and Informed Choice marks, plus a batch certificate of analysis confirming identity and the absence of heavy metals and residual solvents, are the available signals.

  • Reputable suppliers: ConsumerLab’s B Vitamin review names its tested Top Picks for niacin. NOW Foods and Solgar both list plain nicotinic acid at 500 mg; prescription extended-release comes from established generic manufacturers, so compounding is unnecessary.

  • Label verification: The panel should state “niacin (as nicotinic acid)” rather than “niacinamide” or “niacin equivalents”, with the stated milligram figure referring to nicotinic acid itself, not to a blend.

Practical Considerations

  • Time to effect: Lipid and lipoprotein(a) changes reach a plateau in four to six weeks at a stable dose. Flush tolerance develops over two to four weeks. NAD+ effects in deficiency states took months to become measurable.

  • Pitfall — buying the wrong form: The commonest mistake by a wide margin is choosing “flush-free” niacin, which avoids the flush precisely because it does not deliver the pharmacology being sought.

  • Pitfall — escalating too fast: Jumping straight to a gram guarantees a severe flush, and most people stop there. Slow escalation is the difference between an effective and an abandoned protocol.

  • Pitfall — ignoring glucose: Users track lipids and neglect fasting glucose and HbA1c, missing the drift into diabetes that is the best-quantified harm of the compound.

  • Regulatory status: Niacin is sold as a dietary supplement in most countries and as a prescription drug at high doses. The branded combination products were withdrawn, and FDA removed the combination indications in 2016.

  • Cost and accessibility: Immediate-release niacin costs a few dollars monthly; prescription extended-release costs more but stays far below newer lipid drugs. Insurers and health systems therefore have a standing incentive favouring niacin, opposite to the manufacturer funding behind guideline evidence.

Interaction with Foundational Habits

  • Sleep: Direct and usually mild. Evening dosing places the flush and any vasodilation at bedtime, where the warmth is tolerable for most and disruptive for some. Where flushing wakes people, the usual remedies are moving the dose to the evening meal rather than bedtime, or switching to extended-release.

  • Nutrition: Direct and important. Taking each dose with a meal containing fat slows absorption and blunts the flush. Adequate folate, vitamin B12 and choline offset the methyl-group cost of clearing surplus niacin, and adequate tryptophan reduces the requirement.

  • Exercise: Indirect and potentially blunting. Niacin suppresses release of fat from fat tissue, which is a key fuel source during longer sessions, so dosing before endurance work may impair substrate availability. Dosing after the day’s training avoids this entirely.

  • Stress management: Indirect. Niacin has no established effect on cortisol, but its flush closely mimics an anxiety or panic response — heat, flushing, rapid heartbeat — and can be misread as one. Knowing this in advance markedly reduces the distress it causes.

Monitoring Protocol & Defining Success

Before starting, a baseline set establishes both whether there is a target worth treating and whether the main risks are already present. This means a full lipid panel with apolipoprotein B and a once-in-a-lifetime lipoprotein(a) measurement, a liver panel, fasting glucose with HbA1c, serum urate, and high-sensitivity C-reactive protein. Without an elevated apolipoprotein B, lipoprotein(a) or a documented deficiency, there is no measurable endpoint to titrate against.

Ongoing testing follows a fixed cadence: liver enzymes, fasting glucose and lipids at 6–8 weeks after reaching the target dose, again at 6 months, then every 6–12 months while treatment continues. Any dose increase resets the 6–8 week clock. Serum urate is checked at baseline and annually, or sooner if joint symptoms appear. Success means a fall in apolipoprotein B and lipoprotein(a) with glucose, liver enzymes and urate unchanged.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Apolipoprotein B < 80 mg/dL; < 60 mg/dL if high cardiovascular risk Counts every artery-clogging particle; the primary efficacy target Non-fasting acceptable. Conventional labs often report no target at all, only a percentile
Lipoprotein(a) < 75 nmol/L (< 30 mg/dL) The particle niacin lowers that few other agents touch Measured once in a lifetime as a baseline; reported in nmol/L, not mg/dL. Largely genetically fixed
LDL cholesterol < 70 mg/dL if high risk; < 100 mg/dL otherwise Standard efficacy check, though apolipoprotein B is more informative Conventional cut-off of < 130 mg/dL is considerably less strict
HDL cholesterol 50–80 mg/dL Tracks the effect niacin produces most strongly Conventional labs flag only < 40 mg/dL (men) or < 50 mg/dL (women) as low. Rising HDL alone should not be read as benefit — it did not translate into events in trials
Triglycerides < 80 mg/dL Falls early on niacin; a sensitive marker of the fat-release effect Requires a 12-hour fast. Conventional threshold is < 150 mg/dL
Fasting glucose 75–86 mg/dL The earliest signal of niacin’s glucose harm Requires a 10–12 hour fast. Best paired with fasting insulin. Conventional range extends to 99 mg/dL
HbA1c 4.8–5.3% Confirms whether a glucose drift is real rather than day-to-day noise HbA1c = glycated haemoglobin, a three-month average of blood sugar. Conventional cut-off is < 5.7%
Fasting insulin 2–5 µIU/mL Detects rising insulin resistance before glucose moves Conventional reference range runs to roughly 25 µIU/mL, far above the functional target. Best paired with fasting glucose on the same draw to calculate insulin resistance
Alanine aminotransferase 10–26 U/L (men); 8–22 U/L (women) The stop signal for hepatotoxicity Above three times the upper limit on consecutive tests means discontinuation. Conventional upper limits run to 40–55 U/L
Serum urate 3.5–6.0 mg/dL Niacin competes with urate for kidney excretion, precipitating gout Conventional range extends to 7.2 mg/dL, well above the crystal-formation threshold
High-sensitivity C-reactive protein < 1.0 mg/L Tracks the inflammatory effect, which only appears if baseline exceeds 3 mg/L Conventional cardiovascular risk stratification treats anything under 3.0 mg/L as acceptable. Invalid within two weeks of any infection or injury
Homocysteine < 9 µmol/L Screens for strain on methyl-group supply from clearing surplus niacin Conventional upper limits run to about 15 µmol/L. No niacin-specific target exists; the marker to follow is change from the individual’s own baseline. Fasting sample

Qualitative markers worth tracking alongside the laboratory data:

  • Flush intensity and duration, which should shorten over the first month and signals whether escalation is proceeding too fast
  • Energy and exercise tolerance, particularly during longer endurance sessions where fat-fuel availability is affected
  • Muscle soreness or weakness disproportionate to training load, which warrants a creatine kinase test if statins are also being taken
  • Digestive comfort, especially any return of reflux or ulcer-type pain
  • Vision clarity, since blurring of central vision is the presenting sign of niacin maculopathy
  • Sleep quality and any nocturnal warmth or waking attributable to evening dosing

Emerging Research

  • Niacin for fatty liver disease: NCT06843148 is a randomized, quadruple-blind crossover trial in 36 adults with metabolic dysfunction-associated steatotic liver disease, testing 750 mg daily against placebo over two 12-week phases. Primary endpoint is liver fatty-acid flux measured by imaging.

  • Nicotinic acid and glucose production: NCT03540758 is a phase 2 trial at Albert Einstein College of Medicine in 100 participants, using nicotinic acid to probe how the brain regulates the liver’s glucose output — directly relevant to niacin’s diabetes signal.

  • Vitamin B3 forms in peripheral artery disease: NCT07782671 randomizes 250 adults over 50 to nicotinamide riboside or placebo for six months, with six-minute walk distance as the primary endpoint. Tests whether raising NAD+ improves function, not just biochemistry.

  • Vitamin B3 forms in glaucoma: NCT06731582 is a phase 3 trial of 520 participants testing nicotinamide against placebo on visual field loss, which would establish whether the observational niacin–glaucoma association reflects causation.

  • The terminal metabolite question: Ferrell et al., 2024 proposed that 4PY drives residual cardiovascular risk. Confirming or refuting causation would either explain why niacin failed in the statin era or remove the most serious current objection to it.

  • Whether lowering lipoprotein(a) reduces events: Xie et al., 2025 compared lipoprotein(a) lowering across drug classes. Ongoing outcome trials of newer agents will settle whether the reduction niacin produces would translate into fewer events.

  • Conflict-of-interest note on this pipeline: The peripheral artery disease trial above is supplied by ChromaDex, which sells nicotinamide riboside. Generic niacin has no commercial sponsor, and payers gain nothing from displacing a cheap generic, so neither funds equivalent outcome trials.

Conclusion

Niacin occupies an unusual position: an inexpensive nutrient that, at doses hundreds of times the dietary requirement, changes blood fats more broadly than almost any other option sold without a prescription. It lowers the particle count that drives artery disease, and it lowers the inherited cholesterol particle that most other treatments barely touch. Those effects are firmly established and repeatable.

What has not been established is that they translate into fewer heart attacks or longer life. The two large modern trials asked whether niacin adds anything on top of intensive cholesterol-lowering treatment, and both found it does not, while finding real harm: more new diabetes, liver strain, muscle injury when combined with cholesterol drugs, and a flush most people find hard to live with. Both of those trials were funded by the companies selling the products under test, which cuts in more than one direction — and the older studies that found benefit came from an era with no comparable treatment available, so neither body of evidence answers the other’s question.

For someone with a high inherited particle level and no ability or willingness to use standard treatment, the calculation differs from that of a metabolically healthy person adding it speculatively, for whom the diabetes signal is the dominant consideration. The renewed interest coming from cellular ageing research rests, so far, on animal work and one small human trial in a rare muscle disease.

Top - Benefits - Risks - Protocol